What are the advantages of buspirone (Buspar) compared to hydroxyzine (Vistaril) for anxiety relief in a 16‑year‑old adolescent?

Neither Buspirone nor Hydroxyzine Are Guideline-Recommended First-Line Treatments for Anxiety in a 16-Year-Old

For a 16-year-old with anxiety disorders, the 2020 AACAP guideline clearly establishes that cognitive-behavioral therapy (CBT) and SSRIs are the only treatments with "considerable empirical support as safe and effective," while neither buspirone nor hydroxyzine are mentioned as recommended options 1.

The Evidence-Based Treatment Hierarchy

The guideline framework is unambiguous:

• First-line options: CBT (particularly for mild-moderate anxiety) or SSRIs (particularly for severe presentations or when quality CBT is unavailable) 1
• Second-line: SNRIs have "some empirical support" 1
• Not recommended: Buspirone and hydroxyzine are conspicuously absent from the guideline recommendations

Why This Question Presents a False Choice

Buspirone's Limited Evidence in Adolescents

Buspirone failed to separate from placebo in two large randomized controlled trials specifically conducted in children and adolescents aged 6-17 with generalized anxiety disorder 2. The Bayesian reanalysis of these abandoned trials (N=568 total patients) showed:

• No efficacy at low dose (95% CI: -0.78 to 2.39, p=0.32)
• No efficacy at high dose (95% CI: -0.87 to 1.87, p=0.47)
• No efficacy with flexible dosing (95% CI: -0.3 to 1.9, p=0.15)
• Significantly higher dropout rates due to adverse events compared to placebo (p=0.011) 2

While buspirone is FDA-approved for generalized anxiety disorder in adults 3, the FDA label explicitly states "the effectiveness of buspirone hydrochloride tablets in long-term use, that is, for more than 3 to 4 weeks, has not been demonstrated in controlled trials" 3. The adult literature shows a 1-2 week lag time to onset of effect 4, 5, which may reduce adolescent adherence.

Hydroxyzine's Safety Concerns

Hydroxyzine carries significant cardiac risks that are particularly problematic in younger patients:

• Associated with QT prolongation 6
• Can cause sedation and cognitive impairment, unlike buspirone 7
• Not mentioned in the 2020 AACAP anxiety guideline as a treatment option 1

A 2026 case report specifically highlighted hydroxyzine's QT prolongation risk requiring restriction to low doses and close ECG monitoring 6.

The Correct Clinical Approach

If you must choose between these two non-evidence-based options (recognizing this represents suboptimal care):

Buspirone Would Be Marginally Preferable Because:

1. Lower sedation risk: Unlike hydroxyzine, buspirone does not cause sedation or functional impairment 8, 5, 7
2. No abuse potential: Buspirone lacks dependency-producing properties 4, 9, 5
3. Cardiac safety: No QT prolongation concerns, unlike hydroxyzine 6
4. Tolerability: Generally well-tolerated in adolescents despite lack of efficacy 2

Critical Dosing Considerations for Buspirone (If Used):

• Start at 2.5-5 mg twice daily 3
• Titrate slowly over 1-2 weeks as tolerated 3
• Target dose typically 15-30 mg/day divided 3
• Warn patient/family about 1-2 week lag time to effect to maintain adherence 4, 5
• Monitor for lightheadedness (most common side effect in adolescents) 2

However, The Appropriate Recommendation Is:

Reconsider the treatment plan entirely and offer guideline-concordant care:

1. First choice: CBT for mild-moderate anxiety 1
2. Alternative/severe cases: SSRI (fluoxetine, sertraline, fluvoxamine, or paroxetine have pediatric anxiety data) 1
3. Combination: CBT + SSRI for optimal outcomes in moderate-severe cases 1

Common Pitfalls to Avoid

• Don't assume adult buspirone data applies to adolescents - the pediatric trials were definitively negative 2
• Don't use hydroxyzine as chronic anxiety treatment - it's an antihistamine with sedating properties, not an evidence-based anxiolytic in this population 7
• Don't forget the black box warning - if an SSRI is used, monitor closely for suicidal ideation, especially in first months (NNH=143 vs NNT=3 for response) 1
• Don't skip psychotherapy - medication-only approaches miss the most evidence-based intervention 1

The evidence strongly favors redirecting this 16-year-old toward CBT and/or SSRIs rather than choosing between two agents lacking pediatric efficacy data or guideline support 1, 2.